Eli Lilly Enters $1.2 Billion Definitive Agreement to Acquire Ventyx Biosciences

Pharmaceutical Executive January 8, 2026
Nicholas Jacobus

Key Takeaways

• Eli Lilly will acquire Ventyx Biosciences for $1.2 billion to develop oral therapies for inflammatory-mediated diseases.
• The acquisition highlights the industry’s focus on inflammation as a driver of chronic diseases.
• Ventyx’s pipeline includes NLRP3 inhibitors targeting cardiometabolic, neurodegenerative, and autoimmune conditions.
• The transaction is expected to close in the first half of 2026, following regulatory approvals and stockholder consent.

Lilly’s acquisition of Ventyx deepens its inflammation-focused pipeline with a strategic push to secure differentiated oral therapies aimed at chronic, immune-mediated diseases with significant unmet need.

Eli Lilly and Company and Ventyx Biosciences entered into a definitive agreement under which Eli Lilly will acquire Ventyx in an all-cash transaction valued at approximately $1.2 billion to develop innovative...

Today's Sponsors

Today's Sponsor